TWO LAUNCH ANNOUNCEMENTS BY INCYTE
Now approved, a new option for adult patients with relapsed or refractory Diffuse Large B-Cell Lymphoma: Monjuvi
Pemazyre FDA Approved: a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.